Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease

NCT01054768 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Anemia, Sickle Cell

Interventions

DRUG: alpha-lipoic acid and acetyl-L-carnitine
DRUG: Control

Sponsor

UCSF Benioff Children's Hospital Oakland

Collaborators

[object Object]